# Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

> **NCT01844986** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 450 (actual)

## Conditions studied

- Newly Diagnosed
- Advanced Ovarian Cancer
- FIGO Stage III-IV
- BRCA Mutation
- Complete Response
- Partial Response
- First Line Platinum Chemotherapy

## Interventions

- **DRUG:** Olaparib 300mg tablets

## Key facts

- **NCT ID:** NCT01844986
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-08-26
- **Primary completion:** 2018-05-17
- **Final completion:** 2028-08-29
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844986, "Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01844986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*